Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results

By C. Goetz, B. Tilley, Stephanie R. Shaftman, G. Stebbins, S. Fahn, P. Martínez-Martín, W. Poewe, C. Sampaio, M. Stern, R. Dodel and 15 more. Movement Disorders, 2008

7,016 citations recorded by the source corpus.

Subfields: Cognitive Neuroscience, Neurology

View Paper: https://www.semanticscholar.org/paper/61bdcd313e93971d2f58480b703213f8d174c085

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cognitive Neuroscience

1. Bruno Dubois
2. Arthur W. Toga
3. Jose A. Obeso
4. John Q. Trojanowski
5. M. Stamelou
6. Dinggang Shen
7. Heung-Il Suk

In Neurology

1. Eduardo Tolosa
2. Bruno Dubois
3. Arthur W. Toga
4. Jose A. Obeso
5. John Q. Trojanowski
6. Daniel Weintraub

Citations in the corpus

• MDS clinical diagnostic criteria for Parkinson's disease (2015, methodology): “Examination of all cardinal manifestations should be carried out as described in the MDS–Unified Parkinson Disease Rating Scale.(30) Once parkinsonism has been diagnosed: Diagnosis of Clinically Established PD requires: 1.”
• The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018, methodology): “Clinical assessments included Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDSUPDRS) and Hoehn and Yahr scales.(5) Global cognition was assessed with the MoCA.”
• How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale (2013, methodology): “In 2008, the Movement Disorder Society (MDS) released a revision to the UPDRS, called the MDS-UPDRS.(10) In the clinimetric program to establish this new scale, the reliability and factor structure of the MDS-UPDRS were validated using a sample of over 800 PD patients evaluated with both the UPDRS a”
• A Survey of Healthcare Internet-of-Things (HIoT): A Clinical Perspective (2019, background): “Disease progression and efficacy of medications are currently assessed subjectively by physicians via in-clinic-tests that assign patients a score on the Unified Parkinson’s Disease Rating Scale (UPDRS) [127] or the Unified Huntington’s Disease Rating Scale (UHDRS) [128].”
• Cortical dynamics and network alterations in Parkinson’s disease with mild cognitive impairment: TMS-EEG study of the posterior parietal cortex (2025, unknown): “Motor symptoms were primarily evaluated using the Movement Disorder Society Uni fi ed PD Rating Scale part III (MDS-UPDRS III) 38 , comprising four subscale scores for rigidity, tremor, axial, and bradykinesia.”